62 results about "Uveal tract" patented technology

Devices and methods for treating intraocular pressure are disclosed. The devices include shunts for draining aqueous humor from the anterior chamber to the uveoscleral outflow pathway, including the supraciliary space and the suprachoroidal space. The shunts are preferably implanted by ab interno procedures.

Devices and methods for treating intraocular pressure are disclosed. The devices include drug delivery implants for treating ocular tissue. Optionally, the devices also include shunts for draining aqueous humor from the anterior chamber to the uveoscleral outflow pathway, including the supraciliary space and the suprachoroidal space. The drug delivery implants can be implanted in ab interno or ab externo procedures.

Disclosed herein are compositions and methods for treating ocular diseases, inter alia, diabetic macular edema, age-related macular degeneration (wet form), choroidal neovascularization, diabetic retinopathy, retinal vein occlusion (central or branch), ocular trauma, surgery induced edema, surgery induced neovascularization, cystoid macular edema, ocular ischemia, uveitis, and the like. These diseases or conditions are characterized by changes in the ocular vasculature whether progressive or non-progressive, whether a result of an acute disease or condition, or a chronic disease or condition.

Ophthalmically acceptable compositions used in arresting the development of cataract, presbyopia, macular degeneration and other retinopathies, glaucoma, uveitis and various corneal disorders are disclosed. The compositions are also useful as a prophylactic treatment to prevent or delay development of age-related ocular disorders, which include cataracts, presbyopia, glaucoma and macular degeneration. The compositions comprise a pharmaceutically acceptable carrier or diluent and at least one compound having the formula where R1 and R2 are, independently, H or C1 to C3 alkyl ; R3 and R4 are, independently C1 to C3 alkyl; and where R1 and R2, taken together, or R3 and R4, taken together, or both may be cycloalkyl; R5 is H, OH, or C1 to C6 alkyl ; R6 is or C1 to C6 alkyl, alkenyl, alkynyl, or substituted alkyl or alkenyl ; R7 is C1 to C6 alkyl, alkenyl, alkynyl, or substituted alkyl or alkenyl or where R6 and R7, or R5, R6 and R7, taken together, form a carbocycle or heterocycle having from 3 to 7 atoms in the ring.

The invention discloses an application of minocycline hydrochloride to preparation of a medicine for treating autoimmune uveitis and a treatment method of the autoimmune uveitis. The inventor finds that the minocycline hydrochloride can be used as an early intervention medicine by exploring the treatment effect of minocycline with different administration dosages on the autoimmune uveitis. By inhibiting microglial cell activation of retina tissue, reducing immune cell infiltration and reconstructing a steady state in gastrointestinal tract flora, generation and development of the uveitis are effectively inhibited, a new application is provided for application of the minocycline hydrochloride, and besides, a new strategy and method are provided for early prevention and intervention of the autoimmune uveitis.

The invention relates to gene therapy of Leber genetics optic neuropathy. It is accidentally found in the invention that administration of Medrol before and after gene therapy of ocular diseases (i.e., administration of recombinant adeno-associated virus) not only can remarkably improve the treatment effect, but also can effectively prevent and/or treat complications of gene therapy, such as selective cataract removal, uveitis, anterior chamber inflammation and vitreitis, and causes small side effects.

The invention discloses an application of a polypeptide in a medicine for treating eye inflammation. The amino acid sequence of the polypeptide is YGRKKRRQRRRMMPYSTELIFYIEMDP. Eye drops prepared fromthe polypeptide comprise the following components in percentage by weight: 0.05-1% of polypeptide, and the eye inflammation is conjunctivitis, keratitis and/or uveitis. In the polypeptide eye drops, the pharmacological action of the polypeptide in treatment of inflammation is to inhibit inflammation from participating in cell proliferation, inhibit NF-kB activation, inhibit the generation and secretion of various inflammatory mediators, inhibit the growth of new capillaries, inhibit the aggregation and infiltration of inflammatory cells and the like. The polypeptide eye drops are clear in pharmacology, good in curative effect, low in side effect, stable in biological activity of bulk drugs, simple in production process, low in cost and beneficial to large-scale clinical application and reduction of burden of patients.

The present invention relates to a method for simultaneously detecting a plurality of pathogens from biologically-derived samples, and a kit for carrying out the method. Specifically, the present invention relates to a method for simultaneously detecting a plurality of pathogens that cause infectious uveitis, one of eye infections from samples such as anterior chamber fluid or vitreous by polymerase chain reaction (PCR), and a kit for carrying out the method.

The invention is an application of FK-506 macrolide antibiotic and medicine which can be decomposed biologically automatically which are used as planted slow release medicines in eyes. The medicine can maintain a fixed intensity and shape after release, and it can be decomposed naturally in vivo, thus it can be absorbed and discharged out of body, it will not become abnormal and generates stimulation to body, thus it need not to be taken out in the secondary operation. The period of the medicine is from two weeks to half year, the dose needed is little, it will not be affected by tears and dilution, it can release medicine slowly in a long period; it can be applied to prevent the eye diseases and cure repulsion reaction after cornea transplantation, at the same time, it can cure chronic uveitis, behcets disease, stevene-Johnson syndrome, and other diseases.

The present invention relates to the treatment of an ocular inflammatory disease or an ocular degeneration disease by ophthalmic administration of a composition comprising tapinarof and optionally at least one additional active agent. The composition of the present invention is useful for the treatment, prevention and/or alleviation of the symptoms of an ocular inflammatory disease or an ocular degeneration disease selected from uveitis, vitritis, dry eye disease (DED), macular degeneration, idiopathic orbital inflammatory disease (IOD), chorioretinal inflammation, keratitis, blepharitis, seborrheic dermatitis of eyelids, seborrheic dermatitis of eyebrows, hyperemia, thyroid eye disease (TED), age-related macular degeneration, orbital myositis, and combinations thereof.

The present invention relates to the treatment of an ocular inflammatory disease or an ocular degeneration disease by ophthalmic administration of a composition comprising tapinarof and optionally at least one additional active agent. The composition of the present invention is useful for the treatment, prevention and/or alleviation of the symptoms of an ocular inflammatory disease or an ocular degeneration disease selected from uveitis, vitritis, dry eye disease (DED), macular degeneration, idiopathic orbital inflammatory disease (IOD), chorioretinal inflammation, keratitis, age-related macular degeneration and combinations thereof.